Literature DB >> 21814839

Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children.

T P Velavan1, Birgül Büyükyazici, Peter G Kremsner, Jürgen F J Kun.   

Abstract

The critical barrier in control of infections remains the failure of the immune system to clear parasites despite antigen recognition. We examined and validated possible association of regulatory immune gene polymorphisms in a cohort of children with mild and severe malaria. We focussed on two precursors of the Interleukin 10 Receptor (IL10R) gene namely the IL10R alpha and IL10R beta that play a fundamental role in initiation of signal transduction. Initial screening across 40 Gabonese adult individuals revealed two promoter variants for the IL10R alpha and three for the IL10R beta precursor, respectively. Validation of these variants for their allelic gene expression by transient transfection assays exhibited an altered expression in rs56356146 and rs7925112 of the IL10R alpha (P < 0.5); rs8178435 and rs999788 in the IL10R beta constructs (P < 0.0001), respectively. We further investigated the functional role of those SNP variants exhibiting altered expression in a cohort of children with mild and severe malaria. We genotyped 145 children with mild and 185 children with severe malaria for IL10R alpha; for IL10R beta, 102 children with mild and 101 children with severe malaria. We found that none of the SNP variants had any significant association neither in children with mild or severe malaria. The haplotype -185/-116 of IL10R alpha (TT) in combination with the haplotype -754/-750 of IL10R beta (AC) contributed towards mild malaria in comparison to severe malaria [TT + AC odds ratio of 0.73 (95% CI 0.56-0.94) P = 0.01]. This study may provide a better understanding on the role of IL10R promoter allelic variants contribution to a protective effect on the development of severe malaria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814839     DOI: 10.1007/s00251-011-0563-3

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  30 in total

Review 1.  The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions.

Authors:  Jerome A Langer; E Cali Cutrone; Sergei Kotenko
Journal:  Cytokine Growth Factor Rev       Date:  2004-02       Impact factor: 7.638

2.  Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.

Authors:  J Xing; D D Ginty; M E Greenberg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

3.  Increase in annexin V-positive B cells expressing LILRB1/ILT2/CD85j in malaria.

Authors:  Yvonne Kalmbach; Angelica B W Boldt; Rolf Fendel; Benjamin Mordmüller; Peter G Kremsner; Jürgen F J Kun
Journal:  Eur Cytokine Netw       Date:  2006-09       Impact factor: 2.737

4.  Association of the ICAM-1Kilifi mutation with protection against severe malaria in Lambaréné, Gabon.

Authors:  J F Kun; J Klabunde; B Lell; D Luckner; M Alpers; J May; C Meyer; P G Kremsner
Journal:  Am J Trop Med Hyg       Date:  1999-11       Impact factor: 2.345

5.  Interleukin-10 gene promoter polymorphisms and their protein production in pleural fluid in patients with tuberculosis.

Authors:  Li Liang; Yan-Lin Zhao; Jun Yue; Jian-Fang Liu; Min Han; Hongxiu Wang; Heping Xiao
Journal:  FEMS Immunol Med Microbiol       Date:  2011-03-08

6.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block.

Authors:  Mohammad Pashmforoush; Jonathan T Lu; Hanying Chen; Tara St Amand; Richard Kondo; Sylvain Pradervand; Sylvia M Evans; Bob Clark; James R Feramisco; Wayne Giles; Siew Yen Ho; D Woodrow Benson; Michael Silberbach; Weinian Shou; Kenneth R Chien
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

8.  Functional analysis of a promoter variant of the gene encoding the interferon-gamma receptor chain I.

Authors:  Simone Jüliger; Martina Bongartz; Adrian J F Luty; Peter G Kremsner; Jürgen F J Kun
Journal:  Immunogenetics       Date:  2002-12-14       Impact factor: 2.846

9.  Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production.

Authors:  Christoph Gasche; Paul Grundtner; Petra Zwirn; Walter Reinisch; Sarah H Shaw; Alexander Zdanov; Usha Sarma; Lynn M Williams; Brian M Foxwell; Alfred Gangl
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

Review 10.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  8 in total

1.  FOXO3A regulatory polymorphism and susceptibility to severe malaria in Gabonese children.

Authors:  Christian Ngouadjio Nguetse; Peter G Kremsner; Thirumalaisamy P Velavan
Journal:  Immunogenetics       Date:  2014-11-25       Impact factor: 2.846

2.  Candidate human genetic polymorphisms and severe malaria in a Tanzanian population.

Authors:  Alphaxard Manjurano; Taane G Clark; Behzad Nadjm; George Mtove; Hannah Wangai; Nuno Sepulveda; Susana G Campino; Caroline Maxwell; Raimos Olomi; Kirk R Rockett; Anna Jeffreys; Eleanor M Riley; Hugh Reyburn; Christopher Drakeley
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

3.  Genetic evidence of regulatory gene variants of the STAT6, IL10R and FOXP3 locus as a susceptibility factor in uncomplicated malaria and parasitaemia in Congolese children.

Authors:  Felix Koukouikila-Koussounda; Francine Ntoumi; Mathieu Ndounga; Hoang V Tong; Ange-Antoine Abena; Thirumalaisamy P Velavan
Journal:  Malar J       Date:  2013-01-08       Impact factor: 2.979

4.  LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations.

Authors:  Patrick Marcinek; Aditya Nath Jha; Vidyagouri Shinde; Arun Sundaramoorthy; Raja Rajkumar; Naveen Chandra Suryadevara; Sanjeev Kumar Neela; Hoang van Tong; Vellingiri Balachander; Vijaya Lakshmi Valluri; Kumarasamy Thangaraj; Thirumalaisamy P Velavan
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

5.  A reliable and rapid method for molecular detection of malarial parasites using microwave irradiation and loop mediated isothermal amplification.

Authors:  Julia R Port; Christian Nguetse; Selorme Adukpo; Thirumalaisamy P Velavan
Journal:  Malar J       Date:  2014-11-24       Impact factor: 2.979

6.  Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.

Authors:  Christian N Nguetse; Ayola Akim Adegnika; Tsiri Agbenyega; Bernhards R Ogutu; Sanjeev Krishna; Peter G Kremsner; Thirumalaisamy P Velavan
Journal:  Malar J       Date:  2017-05-23       Impact factor: 2.979

7.  In-vitro characterization of novel and functional regulatory SNPs in the promoter region of IL2 and IL2R alpha in a Gabonese population.

Authors:  Xiangsheng Huang; Vera Kühne; Jürgen F J Kun; Peter T Soboslay; Bertrand Lell; Velavan Tp
Journal:  BMC Med Genet       Date:  2012-12-07       Impact factor: 2.103

8.  Co-infection of human parvovirus B19 with Plasmodium falciparum contributes to malaria disease severity in Gabonese patients.

Authors:  Nguyen L Toan; Bui T Sy; Le H Song; Hoang V Luong; Nguyen T Binh; Vu Q Binh; Reinhard Kandolf; Thirumalaisamy P Velavan; Peter G Kremsner; C-Thomas Bock
Journal:  BMC Infect Dis       Date:  2013-08-15       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.